{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:40:15Z","timestamp":1784072415039,"version":"3.55.0"},"reference-count":55,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T00:00:00Z","timestamp":1668297600000},"content-version":"vor","delay-in-days":316,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.csbj.2022.11.030","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T23:49:39Z","timestamp":1668642579000},"page":"6458-6466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacometabolomic study of drug response to antihypertensive medications for hypertension marker identification in Han Chinese individuals in Taiwan"],"prefix":"10.34133","volume":"20","author":[{"given":"Yu-Jen","family":"Liang","sequence":"first","affiliation":[{"name":"Institute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Mao","family":"Chiang","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-li","family":"Xiu","sequence":"additional","affiliation":[{"name":"Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan 35053, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Min","family":"Chung","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Jen","family":"Lo","sequence":"additional","affiliation":[{"name":"Metabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan 33302, Taiwan"},{"name":"Department of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shi","family":"Shiao","sequence":"additional","affiliation":[{"name":"Metabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan 33302, Taiwan"},{"name":"Department of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ling","family":"Cheng","sequence":"additional","affiliation":[{"name":"Metabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan 33302, Taiwan"},{"name":"Department of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chin","family":"Kuo","sequence":"additional","affiliation":[{"name":"Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan 35053, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Chou","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan"},{"name":"Institute of Statistics, National Cheng Kung University, Tainan 70101, Taiwan"},{"name":"Institute of Public Health, National Yang-Ming University, Taipei 11221, Taiwan"},{"name":"Biomedical Translation Research Center, Academia Sinica, Taipei 11529, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Harn","family":"Pan","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212531","article-title":"Combination therapy in the treatment of hypertension","volume":"7","author":"Guerrero-Garcia C.","year":"2018","unstructured":"Guerrero-Garcia C. and Rubio-Guerra A.F.: Combination therapy in the treatment of hypertension. Drugs Context 2018; 7: 212531.","journal-title":"Drugs Context"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.14"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/HJH.0000000000001720","article-title":"Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis","volume":"36","author":"Xie W.","year":"2018","unstructured":"Xie W. et al: Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. J Hypertens 2018; 36: 1256.","journal-title":"J Hypertens"},{"key":"e_1_3_5_5_2","article-title":"Blood pressure, hypertension and the risk of sudden cardiac death: a systematic review and meta-analysis of cohort studies","author":"Pan H.","year":"2019","unstructured":"Pan H. et al: Blood pressure, hypertension and the risk of sudden cardiac death: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2019; .","journal-title":"Eur J Epidemiol"},{"key":"e_1_3_5_6_2","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"11","author":"Chen Y.J.","year":"2018","unstructured":"Chen Y.J. et al: First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2018; 11.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_7_2","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"1","author":"Xue H.","year":"2015","unstructured":"Xue H. et al: First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2015; 1.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_8_2","unstructured":"World Health Organization Guideline for the pharmacological treatment of hypertension in adults 2021 Geneva."},{"key":"e_1_3_5_9_2","first-page":"225","article-title":"2022 guidelines of the taiwan society of cardiology and the taiwan hypertension society for the management of hypertension","volume":"38","author":"Wang T.D.","year":"2022","unstructured":"Wang T.D. et al: 2022 guidelines of the taiwan society of cardiology and the taiwan hypertension society for the management of hypertension. Acta Cardiol Sin 2022; 38: 225.","journal-title":"Acta Cardiol Sin"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5471931","article-title":"Traditional chinese medicine for essential hypertension: a clinical evidence map","volume":"2020","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y. et al: Traditional chinese medicine for essential hypertension: a clinical evidence map. Evid Based Complement Alternat Med 2020; 2020.","journal-title":"Evid Based Complement Alternat Med"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment, and control of hypertension, 1988\u20132008","volume":"303","author":"Egan B.M.","year":"2010","unstructured":"Egan B.M., Zhao Y. and Axon R.N.: US trends in prevalence, awareness, treatment, and control of hypertension, 1988\u20132008. JAMA 2010; 303: 2043.","journal-title":"JAMA"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001521","article-title":"Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs","volume":"4","author":"Hiltunen T.P.","year":"2015","unstructured":"Hiltunen T.P. et al: Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc 2015; 4.","journal-title":"J Am Heart Assoc"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"p. 951-+","DOI":"10.1093\/eurheartj\/ehs455","article-title":"Genes for blood pressure: an opportunity to understand hypertension","volume":"34","author":"Ehret G.B.","year":"2013","unstructured":"Ehret G.B. and Caulfield M.J.: Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J 2013; 34: p. 951-+.","journal-title":"Eur Heart J"},{"key":"e_1_3_5_14_2","first-page":"341","article-title":"Pharmacogenomics and hypertension: current insights","volume":"12","author":"Oliveira-Paula G.H.","year":"2019","unstructured":"Oliveira-Paula G.H. et al: Pharmacogenomics and hypertension: current insights. Pharmacogenom Pers Med 2019; 12: 341.","journal-title":"Pharmacogenom Pers Med"},{"key":"e_1_3_5_15_2","first-page":"7","article-title":"Essential hypertension: a filtered serum based metabolomics study","author":"Ameta K.","year":"2017","unstructured":"Ameta K. et al: Essential hypertension: a filtered serum based metabolomics study. Sci Rep 2017; : 7.","journal-title":"Sci Rep"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40885-020-00157-9","article-title":"Metabolomics profiling in hypertension and blood pressure regulation: a review","volume":"26","author":"Onuh J.O.","year":"2020","unstructured":"Onuh J.O. and Aliani M.: Metabolomics profiling in hypertension and blood pressure regulation: a review. Clin Hypertens 2020; 26: 23.","journal-title":"Clin Hypertens"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","unstructured":"Au A. K.K. Cheng and L.K. Wei Metabolomics Lipidomics and Pharmacometabolomics of Human Hypertension. Hypertension: From Basic Research to Clinical Practice Vol 2 2017. 956: p. 599-613.","DOI":"10.1007\/5584_2016_79"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10654-014-9910-7","article-title":"Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism","volume":"29","author":"Altmaier E.","year":"2014","unstructured":"Altmaier E. et al: Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism. Eur J Epidemiol 2014; 29: 325.","journal-title":"Eur J Epidemiol"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1039\/C1MB05342F","article-title":"Application of plasma lipidomics in studying the response of patients with essential hypertension to antihypertensive drug therapy","volume":"7","author":"Hu C.X.","year":"2011","unstructured":"Hu C.X. et al: Application of plasma lipidomics in studying the response of patients with essential hypertension to antihypertensive drug therapy. Mol BioSyst 2011; 7: 3271.","journal-title":"Mol BioSyst"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057639","article-title":"Pharmacometabolomics reveals racial differences in response to atenolol treatment","volume":"8","author":"Wikoff W.R.","year":"2013","unstructured":"Wikoff W.R. et al: Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS ONE 2013; 8.","journal-title":"PLoS ONE"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/psp4.12017","article-title":"Pharmacometabolomic assessments of atenolol and hydrochlorothiazide treatment reveal novel drug response phenotypes","volume":"4","author":"Rotroff D.M.","year":"2015","unstructured":"Rotroff D.M. et al: Pharmacometabolomic assessments of atenolol and hydrochlorothiazide treatment reveal novel drug response phenotypes. Cpt-Pharmacomet Syst Pharmacol 2015; 4: 669.","journal-title":"Cpt-Pharmacomet Syst Pharmacol"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187729","article-title":"Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension","volume":"12","author":"Hiltunen T.P.","year":"2017","unstructured":"Hiltunen T.P. et al: Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension. PLoS ONE 2017; 12.","journal-title":"PLoS ONE"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10110936","article-title":"Metabolomics of interstitial fluid, plasma and urine in patients with arterial hypertension: new insights into the underlying mechanisms","volume":"10","author":"Chachaj A.","year":"2020","unstructured":"Chachaj A. et al: Metabolomics of interstitial fluid, plasma and urine in patients with arterial hypertension: new insights into the underlying mechanisms. Diagnostics 2020; 10.","journal-title":"Diagnostics"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nprot.2010.50","article-title":"Global metabolic profiling procedures for urine using UPLC-MS","volume":"5","author":"Want E.J.","year":"2010","unstructured":"Want E.J. et al: Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc 2010; 5: 1005.","journal-title":"Nat Protoc"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrneph.2015.176","article-title":"Hypertension pharmacogenomics: in search of personalized treatment approaches","volume":"12","author":"Cooper-DeHoff R.M.","year":"2016","unstructured":"Cooper-DeHoff R.M. and Johnson J.A.: Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol 2016; 12: 110.","journal-title":"Nat Rev Nephrol"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134709","article-title":"Pharmacogenomics of hypertension treatment","volume":"21","author":"Rysz J.","year":"2020","unstructured":"Rysz J. et al: Pharmacogenomics of hypertension treatment. Int J Mol Sci 2020; 21.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_5_27_2","article-title":"Genome-wide association study of young-onset hypertension in the han chinese population of taiwan","volume":"4","author":"Yang H.C.","year":"2009","unstructured":"Yang H.C. et al: Genome-wide association study of young-onset hypertension in the han chinese population of taiwan. PLoS ONE 2009; 4.","journal-title":"PLoS ONE"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.6b00603"},{"key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate \u2013 a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini Y.","year":"1995","unstructured":"Benjamini Y. and Hochberg Y.: Controlling the false discovery rate \u2013 a practical and powerful approach to multiple testing. J R Statist Soc Ser B-Statist Methodol 1995; 57: 289.","journal-title":"J R Statist Soc Ser B-Statist Methodol"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn810"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl923"},{"key":"e_1_3_5_32_2","unstructured":"IUPAC Compendium of Chemical Terminology 2nd ed. (the \u201cGold Book\u201d). Compiled by A. D. McNaught and A. Wilkinson. 1997 blackwell scientific publications oxford."},{"key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/HYPERTENSIONAHA.113.01396","article-title":"Plasma lipidomic profile signature of hypertension in Mexican American families: specific role of diacylglycerols","volume":"62","author":"Kulkarni H.","year":"2013","unstructured":"Kulkarni H. et al: Plasma lipidomic profile signature of hypertension in Mexican American families: specific role of diacylglycerols. Hypertension 2013; 62: 621.","journal-title":"Hypertension"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01931491"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jama.1960.03030030014003","article-title":"Hypotensive agents and pressor substances - the effect of epinephrine, norepinephrine, angiotensin-ii, and others on the secretory rate of aldosterone in man","volume":"174","author":"Laragh J.H.","year":"1960","unstructured":"Laragh J.H. et al: Hypotensive agents and pressor substances - the effect of epinephrine, norepinephrine, angiotensin-ii, and others on the secretory rate of aldosterone in man. JAMA 1960; 174: 234.","journal-title":"JAMA"},{"key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension","volume":"338","author":"Krum H.","year":"1998","unstructured":"Krum H. et al: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998; 338: 784.","journal-title":"N Engl J Med"},{"key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/phrs.1999.0481","article-title":"Endothelial dysfunction and hypertensive vasoconstriction","volume":"40","author":"De Artinano A.A.","year":"1999","unstructured":"De Artinano A.A. and Gonzalez V.L.M.: Endothelial dysfunction and hypertensive vasoconstriction. Pharmacol Res 1999; 40: 113.","journal-title":"Pharmacol Res"},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.jhh.1001139","article-title":"Lipid second messenger regulation: the role of diacylglycerol kinases and their relevance to hypertension","volume":"15","author":"Ohanian J.","year":"2001","unstructured":"Ohanian J. and Ohanian V.: Lipid second messenger regulation: the role of diacylglycerol kinases and their relevance to hypertension. J Hum Hypertens 2001; 15: 93.","journal-title":"J Hum Hypertens"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-1982-3"},{"key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1021\/tx100305b","article-title":"Lysophosphatidylcholine is generated by spontaneous deacylation of oxidized phospholipids","volume":"24","author":"Choi J.","year":"2011","unstructured":"Choi J. et al: Lysophosphatidylcholine is generated by spontaneous deacylation of oxidized phospholipids. Chem Res Toxicol 2011; 24: 111.","journal-title":"Chem Res Toxicol"},{"key":"e_1_3_5_41_2","article-title":"Prehypertension-associated elevation in circulating lysophosphatidlycholines, Lp-PLA(2) activity, and oxidative stress","volume":"9","author":"Kim M.","year":"2014","unstructured":"Kim M. et al: Prehypertension-associated elevation in circulating lysophosphatidlycholines, Lp-PLA(2) activity, and oxidative stress. PLoS ONE 2014; 9.","journal-title":"PLoS ONE"},{"key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1161\/01.HYP.37.1.154","article-title":"Antibodies to lysophosphatidylcholine are decreased in borderline hypertension","volume":"37","author":"Wu R.H.","year":"2001","unstructured":"Wu R.H. et al: Antibodies to lysophosphatidylcholine are decreased in borderline hypertension. Hypertension 2001; 37: 154.","journal-title":"Hypertension"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2007.00004.x"},{"key":"e_1_3_5_44_2","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0893-133X(01)00341-4","article-title":"The hypnotic actions of the fatty acid amide, oleamide","volume":"25","author":"Mendelson W.B.","year":"2001","unstructured":"Mendelson W.B. and Basile A.S.: The hypnotic actions of the fatty acid amide, oleamide. Neuropsychopharmacology 2001; 25: S36.","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703051"},{"key":"e_1_3_5_46_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/0019-5359.104787","article-title":"Hypertension: salt restriction, sodium homeostasis, and other ions","volume":"65","author":"Gupta N.","year":"2011","unstructured":"Gupta N., Jani K.K. and Gupta N.: Hypertension: salt restriction, sodium homeostasis, and other ions. Indian J Med Sci 2011; 65: 121.","journal-title":"Indian J Med Sci"},{"key":"e_1_3_5_47_2","first-page":"158","article-title":"Modulation by nitric oxide of hypothalamic GABA and serotonin release: implication for central blood pressure regulation","volume":"356","author":"Kaehler S.T.","year":"1997","unstructured":"Kaehler S.T., Philippu A. and Singewald N.: Modulation by nitric oxide of hypothalamic GABA and serotonin release: implication for central blood pressure regulation. Naunyn-Schmiedebergs Arch Pharmacol 1997; 356: 158.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.004697"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2001.7792"},{"key":"e_1_3_5_50_2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1028415X.2020.1831262","article-title":"A review on neuropharmacological role of erucic acid: an omega-9 fatty acid from edible oils","volume":"25","author":"Kumar J.B.S.","year":"2022","unstructured":"Kumar J.B.S. and Sharma B.: A review on neuropharmacological role of erucic acid: an omega-9 fatty acid from edible oils. Nutr Neurosci 2022; 25: 1041.","journal-title":"Nutr Neurosci"},{"key":"e_1_3_5_51_2","doi-asserted-by":"crossref","first-page":"10168","DOI":"10.1074\/jbc.RA120.013583","article-title":"Peroxisomal oxidation of erucic acid suppresses mitochondrial fatty acid oxidation by stimulating malonyl-CoA formation in the rat liver","volume":"295","author":"Chen X.C.","year":"2020","unstructured":"Chen X.C. et al: Peroxisomal oxidation of erucic acid suppresses mitochondrial fatty acid oxidation by stimulating malonyl-CoA formation in the rat liver. J Biol Chem 2020; 295: 10168.","journal-title":"J Biol Chem"},{"key":"e_1_3_5_52_2","first-page":"1373","article-title":"Is dietary erucic acid hepatotoxic in pregnancy? An experimental study in rats and hamsters","volume":"21","author":"Reyes H.","year":"1995","unstructured":"Reyes H. et al: Is dietary erucic acid hepatotoxic in pregnancy? An experimental study in rats and hamsters. Hepatology 1995; 21: 1373.","journal-title":"Hepatology"},{"key":"e_1_3_5_53_2","doi-asserted-by":"crossref","first-page":"p. 1512-+","DOI":"10.1161\/CIRCULATIONAHA.112.001197","article-title":"Long-chain monounsaturated fatty acids and incidence of congestive heart failure in 2 prospective cohorts","volume":"127","author":"Imamura F.","year":"2013","unstructured":"Imamura F. et al: Long-chain monounsaturated fatty acids and incidence of congestive heart failure in 2 prospective cohorts. Circulation 2013; 127: p. 1512-+.","journal-title":"Circulation"},{"key":"e_1_3_5_54_2","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1248\/cpb.34.3025","article-title":"Angiotensin converting enzyme-inhibitory triterpenes from Ganoderma lucidum","volume":"34","author":"Morigiwa A.","year":"1986","unstructured":"Morigiwa A. et al: Angiotensin converting enzyme-inhibitory triterpenes from Ganoderma lucidum. Chem Pharm Bull (Tokyo) 1986; 34: 3025.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"e_1_3_5_55_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cpt.134","article-title":"Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine","volume":"98","author":"Kaddurah-Daouk R.","year":"2015","unstructured":"Kaddurah-Daouk R., Weinshilboum R. and Network P.R.: Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine. Clin Pharmacol Ther 2015; 98: 71.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_5_56_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/HYPERTENSIONAHA.121.18192","article-title":"Hypertension pharmacological treatment in adults: a world health organization guideline executive summary","volume":"79","author":"Al-Makki A.","year":"2022","unstructured":"Al-Makki A. et al: Hypertension pharmacological treatment in adults: a world health organization guideline executive summary. Hypertension 2022; 79: 293.","journal-title":"Hypertension"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037022005232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037022005232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2022.11.030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T15:47:04Z","timestamp":1779032824000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2022.11.030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":55,"alternative-id":["10.1016\/j.csbj.2022.11.030"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2022.11.030","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacometabolomic study of drug response to antihypertensive medications for hypertension marker identification in Han Chinese individuals in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2022.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}